Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We with Cardiac Cell-Based Therapy?

Cristina Sanina, Joshua M. Hare

Research output: Contribution to journalArticle


Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.

Original languageEnglish (US)
Pages (from-to)229-233
Number of pages5
JournalCirculation Research
Issue number3
StatePublished - Jul 17 2015
Externally publishedYes



  • cell- and tissue-based therapy
  • chronic heart failure
  • clinical trial
  • heart disease
  • mesenchymal stem cells

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this